Publications by authors named "G I Shapiro"
Src homology-2 domain-containing phosphatase 2 (SHP2) promotes RAS-MAPK signaling and tumorigenesis and is a promising therapeutic target for multiple solid tumors. Migoprotafib is a potent and highly selective SHP2 inhibitor designed for the treatment of RAS-MAPK driven cancers, particularly in combination with other targeted agents. Here we report first-in-human study results of single agent migoprotafib in advanced solid tumor patients.
View Article and Find Full Text PDFArticle Synopsis
- PARG (poly (ADP-ribose) glycohydrolase) is an enzyme that helps repair DNA by removing poly (ADP-ribose), and inhibiting it can lead to increased DNA damage and sensitize cancer cells to treatments.
- Inhibiting PARG leads to the buildup of single-stranded DNA gaps (ssGAPs) during DNA replication, similar to the effects of PARP inhibitors, particularly in cancer cells that are sensitive to treatment.
- Research shows that treatment with PARG inhibitors (PARGi) not only affects homologous recombination-deficient cancer cells but also has potential effectiveness in certain homologous recombination-proficient tumors, suggesting patient-derived organoids could be key
Background: HPV test-based primary cervical screening is replacing cytology in Canada. In other countries, women's unpreparedness and concerns hindered the transition and post-implementation screening uptake. We investigated psychosocial correlates of intentions of screening in eligible individuals to participate in HPV-based primary cervical screening.
View Article and Find Full Text PDFArticle Synopsis
- This study looked at why certain embedded performance validity indicators (EVIs) lead to higher false-positive rates (FPRs) in ADHD evaluations among adults, focusing on 15 EVIs from six cognitive tests.
- The research involved 517 adults with ADHD and found that while some EVIs had FPRs over 10% when used alone, combining them reduced the overall FPR to 8.1%.
- The study concluded that the choice of tests and the number of EVIs used are crucial for reducing FPRs in ADHD assessments, emphasizing the need for more refined approaches to test validity.
Background: Preclinical studies have identified molecular correlates of sensitivity to ATR inhibition. This translational study was designed to test the ATR inhibitor berzosertib in patients with advanced solid tumors carrying alterations in ATRX, ATM, genes conferring replication stress (RS), or SDH.
Methods: Patients were recruited to 4 cohorts: T1: ATRX-mutant leiomyosarcoma; T2: ATM-mutant solid tumors; T3: solid tumors with mutations in RS-associated genes; and T4: SDH-deficient GIST.